OSE.PA • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold OSE.PA in your mock portfolio yet.
OSE Immunotherapeutics SA is currently loss-making, as indicated by its negative EPS and negative P/E ratio. This suggests that the company has not yet reached sustainable profitability and is likely still in an investment-heavy, R&D-focused phase typical of small biotech firms. Without evidence of improving earnings trends or clear visibility to near-term profitability, the financial profile remains weak from an equity investor’s standpoint.
The stock trades at €4.60, below its 200-day moving average of €5.63, signaling a prevailing downtrend. A 6.2% decline over the last month and an RSI of 38.88 indicate weak momentum with the stock leaning toward oversold territory but not yet at a clear reversal signal. Overall, technicals point to continued pressure with only a tentative possibility of a short-term bounce if selling abates.
Alternative data for OSE Immunotherapeutics SA is modest and relatively stable, without strong positive or negative inflections. Web traffic is low but not collapsing, job postings are at zero, and social media presence is small with flat-to-slightly-declining engagement on Twitter/X but a more established base on LinkedIn. These signals collectively suggest limited current growth momentum in investor or customer engagement, but not an outright deterioration.
Taken together, OSE Immunotherapeutics SA’s negative earnings profile, weak price action below its 200-day moving average, and subdued alternative data signals point to a bearish overall setup. While the RSI suggests the stock is approaching mildly oversold territory that could support short-term stabilization, there is limited evidence of improving fundamentals or strengthening investor interest. Until there is clearer progress toward profitability or positive clinical/partnership catalysts, the risk-reward profile appears skewed to the downside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: